Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2011 - 2026)

Alnylam Pharmaceuticals' Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $63.6 million for Q1 2026.

• Quarterly Other Non-Current Assets fell 13.91% year-over-year to $63.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.6 million (down 13.91% YoY) and the FY2025 annual result came in at $59.5 million, down 8.96% from the prior year.
• Other Non-Current Assets was $63.6 million for Q1 2026 at Alnylam Pharmaceuticals, up from $59.5 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $92.7 million in Q2 2023 and bottomed at $55.8 million in Q3 2025.
• A 5-year average of $68.2 million and a median of $66.1 million in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 123.4% — and 2025, when it slipped 28.06%.
• Alnylam Pharmaceuticals' Other Non-Current Assets stood at $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then advanced by 5.51% to $65.3 million in 2024, then decreased by 8.96% to $59.5 million in 2025, then advanced by 6.88% to $63.6 million in 2026.
• Business Quant data shows ALNY's Other Non-Current Assets at $63.6 million in Q1 2026, $59.5 million in Q4 2025, and $55.8 million in Q3 2025.